Drug Trial Radar · NCT06614322
SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
190
Planned (sponsor's estimate)
Start
Feb 2, 2026
Primary completion
Jun 1, 2028
Study completion Jun 1, 2028
Sponsor
- Lead sponsor
- University of RochesterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Beth Israel Deaconess Medical Center
- First posted
- Sep 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to determine whether quantitative sensory testing (QST) can be used to classify participants into pain sub-groups and predict who will respond best to certain pain treatments in participants with painful peripheral neuropathy. The analgesic effect is evaluated by measuring pain intensity and Patient Global Impression of Change (PGIC). This study is a 3-period cross-over trial. This means researchers will compare 3 different drugs (pregabalin, duloxetine, and placebo) over a period of 19 weeks. Participants will: * Undergo a quantitative sensory testing (QST) exam. * Provide a blood sample. * Complete questionnaires on the computer. * Take the study drug as instructed.
Conditions
- Painful Peripheral Neuropathy
- Diabetic Peripheral Neuropathic Pain (DPN)
- Chemotherapy Induced Peripheral Neuropathy (CIPN)
- Idiopathic Peripheral Neuropathy
Interventions
PregabalinDrug
300mg/day pregabalin capsule
DuloxetineDrug
60mg/day duloxetine capsule
PlaceboOther
Placebo capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain IntensityTime frame: From enrollment to end of treatment period at 4 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Beth Israel Deaconess Medical Center for Autonomic and Peripheral Nerve Disorders
Boston, Massachusetts · Recruiting
Ichan School of Medicine at Mount Sinai
New York, New York · Recruiting
University of Rochester
Rochester, New York · Recruiting
University of Pittsburgh
Pittsburgh, Pennsylvania · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
University of Vermont
Burlington, Vermont · Recruiting
VCU Medical Center
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.